化合物详情

Pesticide Ecotoxicity Data from EPA: 48

EC50; Species: Daphnia magna (Water flea, age <24 hr); Conditions: freshwater, static; Concentration: 26000 ug/L for 48 hr (95% confidence limit: 21000-31000 ug/L); Effect: intoxication, immobilization /96.2% purity/

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), cyproconazole, which has vapor pressure of 2.59X10-7 mm Hg at 20 °C(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase cyproconazole is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 26 hours(SRC), calculated from its rate constant of 1.5X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Particulate-phase cyproconazole may be removed from the air by wet or dry deposition(SRC). Cyproconazole does not contain chromophores that absorb at wavelengths >290 nm(4) and therefore is...

The Koc of cyproconazole is estimated as 900(SRC), using a log Kow of 2.90(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that cyproconazole is expected to have low mobility in soil.

The mobility and persistence of cyproconazole [alpha-(4-chlorophenyl)-alpha-(1-cyclopropylethyl)-1H-1,2,4-triazole-1-ethanol] on bare soil (Flanagan silt loam; fine, smectitic, mesic Aquertic, Argiudoll) and turf containing varying levels of organic matter was examined under field conditions. Twenty-centimeter-diameter polyvinyl chloride (PVC) cylinders were installed in either creeping bentgrass turf (Agrostis palustris Huds.), or in turf in where either 33, 67, or 100% of the thatch and plant material had been removed. Cyproconazole was applied at 403 g a.i. ha-1 on 15 July 1996 and 8 July 1997. Replicate sampling cylinders were removed 2 hrs after treatment (HAT) and 4, 8, 16, 32, 64, and 128 days after treatment (DAT). Cylinder cores were sectioned into depths and assayed for cyproc...

An estimated BCF of 38 was calculated in fish for cyproconazole(SRC), using a log Kow of 2.90(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is moderate(SRC).

The Henry's Law constant for cyproconazole is estimated as 7.1X10-10 atm-cu m/mole(SRC) derived from its vapor pressure, 2.59X10-7 mm Hg(1), and water solubility, 140 mg/L(1). This Henry's Law constant indicates that cyproconazole is expected to be essentially nonvolatile from water surfaces(2). Cyproconazole's estimated Henry's Law constant indicates that volatilization from moist soil surfaces may not occur(SRC). The potential for volatilization of cyproconazole from dry soil surfaces may exist(SRC) based upon its vapor pressure(1).

The rate constant for the vapor-phase reaction of cyproconazole with photochemically-produced hydroxyl radicals has been estimated as 1.48X10-11 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about 26 hours at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). Cyproconazole is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(2). Cyproconazole does not contain chromophores that absorb at wavelengths >290 nm(2) and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Cyproconazole's production may result in its release to the environment through various waste streams; its former use in the US as an broad spectrum fungicide(1) resulted in its direct release to the environment(SRC).

Occupational exposure to cyproconazole may occur through inhalation and dermal contact with this compound at workplaces where cyproconazole is produced or used. (SRC)

Cyproconazole's production may result in its release to the environment through various waste streams; its use in the US as a broad spectrum fungicide resulted in its direct release to the environment. If released to air, a vapor pressure of 2.59X10-7 mm Hg at 20 °C indicates cyproconazole will exist in both the vapor and particulate phases in the atmosphere. Vapor-phase cyproconazole will be degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals; the half-life for this reaction in air is estimated to be 26 hours. Particulate-phase cyproconazole will be removed from the atmosphere by wet or dry deposition. Cyproconazole does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by...

collection=toxvaldb&kind=^EL$

collection=toxvaldb&kind=^LD$

collection=toxvaldb&kind=^EC$

collection=toxvaldb&kind=^LC$

Oral Chronic Reference Dose Reference: OPP

No indication of carcinogenicity to humans (not listed by IARC).

LD50 Rat oral 2054 mg/kg in males and females

collection=toxvaldb&kind=^RRV$

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a subchronic oral toxicity study, SAN 619 A (cyproconazole, 95.5% ai) was administered to 15 Wistar rats/sex/dose in the diet at dose levels of 0, 20, 350, 700, or 1400 ppm for 13 weeks. FIve rats.sex.dose were subjected to neuropathological examination,a nd also evaluated in the functional observational battery, and for the assessment of motor activity. NO treatment-related effect was observed on survival, clinical signs, the functional observational battery, food consumption ratios, water consumption, the eyes, gross pathology or neuropathology. Ta >/= 350 ppm, absolute and relative to body liver weights were increased (p </=0.05) by 13-55% in both sexes. Increased incidences of liver fatty changes in males and liver hypertrop...

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use...